AstraZeneca shares in tentative rebound

AstraZeneca, the pharmaceutical giant, posted 3Q core EPS fell 4% on year to 0.94 dollar on revenue of 6.58 billion dollars, up 3% (+3% at constant exchange rate), above expectations.

Uptrend 2

AstraZeneca, the pharmaceutical giant, posted 3Q core EPS fell 4% on year to 0.94 dollar on revenue of 6.58 billion dollars, up 3% (+3% at constant exchange rate), above expectations. The company said "total Revenue is expected to increase by a high single-digit to a low double-digit percentage and Core EPS is expected to increase by a mid- to high-teens percentage". 

The U.K. drug agency has begun evaluating the future vaccine developed by AstraZeneca and Oxford University. AstraZeneca is expected to publish the results of much-anticipated advanced clinical trials in the coming weeks

From a chartist point of view, the stock price is reversing up thanks to the upside breakout of a former downward-sloping channel. The bullish gap opened yesterday above the 50DMA is a positive signal. In addition, the daily RSI (14) has broken above a key declining trend line. Readers may want to consider the potential for opening Long positions above the support at 7963p with 8848p and 9650p as targets. Only a break below 7963p would invalidate the bullish bias.

Source: GAIN Capital, TradingView


More from Epidemic

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.